Femasys (FEMY) Total Non-Current Liabilities (2020 - 2026)
Femasys (FEMY) posted Total Non-Current Liabilities of $6.1 million for Q1 2026, down 46.07% on a QoQ basis from $11.2 million in Q4 2025, and up 320.16% year-over-year from $1.4 million in Q1 2025.
Femasys (FEMY) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Femasys' Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $6.1 million for Q1 2026.
- Quarterly Total Non-Current Liabilities rose 320.16% year-over-year to $6.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.1 million (up 320.16% YoY) and the FY2025 annual result came in at $11.2 million, up 620.2% from the prior year.
- Total Non-Current Liabilities was $6.1 million for Q1 2026 at Femasys, down from $11.2 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $11.2 million in Q4 2025 and bottomed at $56245.0 in Q2 2023.
- A 5-year average of $3.1 million and a median of $1.4 million in 2025 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2024 — Total Non-Current Liabilities soared 11567.19% — and 2025, when it slumped 82.33%.
- Femasys' Total Non-Current Liabilities stood at $125242.0 in 2022, then soared by 4969.53% to $6.3 million in 2023, then slumped by 75.47% to $1.6 million in 2024, then surged by 620.2% to $11.2 million in 2025, then slumped by 46.07% to $6.1 million in 2026.
- Business Quant data shows FEMY's Total Non-Current Liabilities at $6.1 million in Q1 2026, $11.2 million in Q4 2025, and $1.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alcon | 32,734,969.19 Bn | 32,734,967.53 Bn | 1.53 Bn | 6.48 Bn |
| 2 | Intuitive Surgical | 117.50 Bn | 112.41 Bn | 1.96 Bn | 1.92 Bn |
| 3 | Becton Dickinson | 42.93 Bn | 42.11 Bn | 2.15 Bn | 48.37 Bn |
| 4 | Medline | 30.82 Bn | 36.66 Bn | 1.84 Bn | 17.13 Bn |
| 5 | Resmed | 27.90 Bn | 26.23 Bn | 890.98 Mn | 941.16 Mn |
| 6 | West Pharmaceutical Services | 26.76 Bn | 26.23 Bn | 329.20 Mn | 996.30 Mn |
| 7 | Cooper Companies | 15.30 Bn | 15.16 Bn | 735.40 Mn | 4.24 Bn |
| 8 | Solventum | 13.46 Bn | 12.90 Bn | 1.10 Bn | 8.65 Bn |
| 9 | Align Technology | 12.02 Bn | 10.96 Bn | 736.59 Mn | 2.06 Bn |
| 10 | Femasys | 17.46 Mn | 12.07 Mn | - | 6.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.05 Mn |
| Dec 31, 2025 | 11.22 Mn |
| Sep 30, 2025 | 1.19 Mn |
| Jun 30, 2025 | 1.31 Mn |
| Mar 31, 2025 | 1.44 Mn |
| Dec 31, 2024 | 1.56 Mn |
| Sep 30, 2024 | 6.75 Mn |
| Jun 30, 2024 | 6.56 Mn |
| Mar 31, 2024 | 6.41 Mn |
| Dec 31, 2023 | 6.35 Mn |
| Sep 30, 2023 | 2.22 Mn |
| Jun 30, 2023 | 56,245.00 |
| Mar 31, 2023 | 98,818.00 |
| Dec 31, 2022 | 125,242.00 |
| Sep 30, 2022 | 217,577.00 |
| Jun 30, 2022 | 318,237.00 |
| Mar 31, 2022 | 407,573.00 |
| Dec 31, 2021 | 552,208.00 |
| Sep 30, 2021 | 690,767.00 |
| Jun 30, 2021 | 788,469.00 |